Biomagnetics goes East for expansion:
This article was originally published in Clinica
Executive Summary
Biomagnetics Diagnostics is to set up a subsidiary in China in a bid to capitalise on the growth opportunities in that market as well as in the rest of Asia. The business unit will be a publicly-listed company trading on either the Shenzhen or Hong Kong stock exchange, said the Orangevale, California-based company. The move is part of the firm's global marketing strategy for its high thoroughput screening-magnetic testing platform (HTS-MTP). The technology is designed to provide both qualitative and quantitative detection of any pathogen, including HIV, in minutes at a low cost, according to Biomagnetics.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.